Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced two independent academic collaborations, one with The University of Texas MD Anderson Cancer Center and the other with Memorial Sloan Kettering. In each of these collaborations, Adimab will use its proprietary yeast-based discovery platform to generate IgGs for development as therapeutic products. MD Anderson and Memorial Sloan Kettering retain full commercial rights to therapeutic products generated in their respective projects. Adimab will also use its recently launched rapid B-cell sorting capabilities in one or more of the programs.

Read More